congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Other/Multi
AACR 2024 | April 5-10, 2024
Targeted proteomics and next-generation sequencing (NGS) for biomarker discovery in metastatic colorectal cancer (mCRC)
Poster
T-DXd
AACR 2024 | April 5-10, 2024
Trastuzumab deruxtecan in Chinese patients with previously treated HER2 mutant non-small cell lung cancer: Primary analysis from the phase 2 DESTINY-Lung05 trial
Poster
Dato-DXd
AACR 2024 | April 5-10, 2024
Tumour growth inhibition modeling and simulation to support dose justification of datopotamab deruxtecan (Dato-DXd) in HR-positive, HER2-negative breast cancer patients
Pages:
1 2